Abstract

BackgroundSeveral cardioprotective mechanisms attributed to n-3 polyunsaturated fatty acids (PUFAs) have been widely documented. Significant interest has recently focused on the role of human gut microbiota in metabolic disorders. However, the role of plant-derived n-3 PUFAs on blood lipid profiles is controversial and the effect on gut microbiota is still unclear.ObjectivesWe aimed to perform a double-blind randomized controlled trial to test the effect of plant-derived n-3 PUFAs on the blood lipids and gut microbiota of patients with marginal hyperlipidemia.MethodsAccording to the inclusion and exclusion criteria, 75 participants with marginal hyperlipidemia were randomly assigned to the intervention group (supplied with n-3 PUFA-enriched plant oil) or control group (supplied with corn oil), respectively, for a 3-month treatment. Participants and assessors were blinded to the allocation. The primary outcomes of the trial were the changes in serum lipid levels. Secondary outcomes were changes in gut microbiota and metabolites. For the primary outcomes, we conducted both an intent-to-treat (ITT) analysis and a per protocol (PP) analysis. For the secondary outcomes, we only conducted the PP analysis among the participants who provided fecal sample.ResultsFifty-one participants completed the trial. Relative to the control group, the n-3 PUFA supplementation resulted in significant reduction in total cholesterol (TC) levels (−0.43 mmol/L, 95% CI−0.84 to−0.01 mmol/L, P < 0.05). The n-3 PUFA supplementation was also associated with significantly increased relative abundance of Bacteroidetes in phylum level (P < 0.01; false discovery rate (FDR) corrected p = 0.11), and decreased the ratio between Firmicutes and Bacteroidetes (P < 0.05; FDR corrected p = 0.16). At genus level, the intervention of plant derived n-3 PUFAs resulted in a significant decrease in relative abundance of Phascolarctobacterium (P < 0.01; FDR corrected p = 0.18) and Veillonella (P < 0.01; FDR corrected p = 0.18) after the intervention.ConclusionsOur results demonstrated that plant-derived n-3 PUFAs beneficially affected the serum levels of TC and decreased the ratio between Firmicutes and Bacteroidetes during the 12-week intervention period, which might confer advantageous consequences for lipid metabolism and intestinal health.

Highlights

  • Hyperlipidemia is an important risk factor for coronary heart disease and stroke [1]

  • We aimed to perform a double-blind randomized controlled trial to test the effect of plant-derived n-3 polyunsaturated fatty acids (PUFAs) on the blood lipids and gut microbiota of patients with marginal hyperlipidemia

  • There was no significant correlation between the relative abundance of gut microbiota and the fecal short-chain fatty acids (SCFAs). In this randomized controlled trial in subjects with marginal hyperlipidemia, increased docosapentaenoic acid (DPA) concentrations in plasma and eicosapentaenoic acid (EPA) concentrations in erythrocyte phospholipids were observed in the intervention group compared with the control group, which providing unbiased support for subject compliance to the protocol

Read more

Summary

Introduction

Hyperlipidemia is an important risk factor for coronary heart disease and stroke [1]. Realizing the goal of fatty fish consumption is obstructed by the food preferences and by concerns about the bio-enrichment of heavy metals [8]. This has increased the interest in the health benefits of n-3 PUFAs derived from plants, including alpha-linolenic acid (ALA) from flaxseed, rapeseed, and camelina oils, and stearidonic acid (SDA) from echium oil [9]. The role of plant-derived n-3 PUFAs in the of lipid metabolism has not been well illustrated and their effects on blood lipid profiles are still controversial [10–15]. The role of plant-derived n-3 PUFAs on blood lipid profiles is controversial and the effect on gut microbiota is still unclear

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call